Drug intelligence / Profile preview

BR1019-2

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1019-2 is an orally administered small molecule drug candidate developed by Boryung Pharmaceutical for the treatment of essential hypertension and type 2 diabetes mellitus. It has been evaluated in phase I clinical trials, including studies focused on pharmacokinetics and safety in healthy volunteers. The precise mechanism of action for BR1019-2 remains undefined, and it is not classified as a new molecular entity. Clinical development has primarily taken place in South Korea, with Boryung Pharmaceutical serving as both sponsor and developer[1][3][5].

Beyond the preview

Go deeper on BR1019-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1019-2.

Explore the full profile